Geographic Area – Page 21

Navigating the Complexities of Adding Rare Disease Products to Your Company’s Portfolio

10 months ago talkbio0Tagged Access, biopharmaceutical development, commercialization, Contract Strategy, Identification (Psychology), Market, Rare disease products, regulatory incentives, Technology, value-based

Rare disease products, biopharmaceutical development, commercialization, market access, patient identification, payer contract strategy, value-based contracting, regulatory incentives, emerging technology.

Johnson & Johnson Invests €580 Million in Italian Manufacturing Operations Over Five Years

10 months ago talkbio0Tagged Capacity, development aspects, Drug Industry, Investments, Italy, Johnson and Johnson, Manufacture, research, Upgrade

Johnson & Johnson, Italy, Manufacturing, Investment, Capacity Upgrade, Research and Development, Pharmaceutical Industry

Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence

11 months ago talkbio0Tagged amber, closed-loop implant, Neurostimulation/modulation, Pelvis, regulatory approval, Structure of pudendal nerve, U.S., United States, Urinary Incontinence

Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.

Kyowa Kirin Invests $530M in First North American Biologics Manufacturing Facility

11 months ago talkbio0Tagged Biological Factors, Investments, Kyowa Kirin, Manufacture, North America, North Carolina

Kyowa Kirin, biologics manufacturing, North America, investment, North Carolina

Skye Bioscience Abandons Eye Disease Pipeline, Shifts Focus to Obesity Treatment After Phase 2a Trial Failure

11 months ago talkbio0Tagged Bioscience, biotech company, Obesity, Prices, Skye, Trial Phase 2A

Skye Bioscience, eye disease, Phase 2a trial, obesity treatment, stock price, biotech company

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

11 months ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)